EMA Authorised: Pregabalin Viatris (previously Pregabalin Mylan) (pregabalin) — Viatris Limited

View source ↗

Summary

The EMA authorised Pregabalin Viatris for anxiety disorders and epilepsy, with Viatris Limited as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders
• Epilepsy

Drugs mentioned

• Pregabalin Viatris (pregabalin)

Snippet

Status: Authorised. Therapeutic area: Anxiety Disorders;Epilepsy. MAH: Viatris Limited. Decision date: 19/12/2025